107results about How to "Reduce cell viability" patented technology

The present invention relates to recombinant Rhabdoviridae, isolated nucleic acids, vectors, cells and compositions comprising same. The recombinant Rhabdoviridae, isolated nucleic acids, vectors, cells and compositions express Rhabdoviral proteins including a mutated matrix protein (M) and/or a mutated glycoprotein (G), in addition to expression of at least one foreign nucleic acid. The present invention also relates to methods of use thereof, including their use in vivo, in anti-cancer applications, such as in the treatment of gliomas. The recombinant Rhabdoviridae of the present invention are also useful in gene therapy and vaccine applications.

The invention relates to a novel elongase gene with the sequence SEQ ID NO: 1 or its homologs, derivatives or analogs, to a gene construct comprising this gene or its homologs, derivatives and analogs, and to its use. The invention also relates to vectors or organisms comprising an elongase gene with the sequence SEQ ID No: 1 or its homologs, derivatives or analogs. Furthermore, the invention relates to a process for the preparation of polyunsaturated fatty acids and to a process for introducing DNA into organisms which produce large amounts of oils and, in particular, oils with a high content of unsaturated fatty acids. Moreover, the invention relates to an oil and/or a fatty acid preparation with a higher content of polyunsaturated fatty acids with at least two double bonds and/or a triacyiglycerol preparation with a higher content of polyunsaturated fatty acids with at least two double bonds.

The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided.

The invention comprises a process for producing a protein of interest in a perfusion system using induction agents without a substantial loss of cell viability. The invention also comprises methods of growing cells in a perfusion system using induction agents without a substantial loss of cell viability.

Provided are methods and compositions for maintaining the viability of photoreceptor cells and/or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and/or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder.

New antisense oligonucleotide compounds inhibit expression of Akt-1 and also induce cytotoxicity in several cancer cell lines.

A method for cryopreservation of a tissue equivalent whereby the viability of frozen cells and the biological activity of thawed cells are improved and the steps are simplified; and a cryopreserved tissue equivalent obtained by the method. Cells suspended in a cryopreserving solution are inoculated into a matrix and then frozen before the cells adhere to the matrix.

Provided are methods and compositions for maintaining the viability of retinal ganglion cells in a subject with an ocular disorder including, for example, glaucoma and optic nerve injury. The viability of the retinal ganglion cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells and/or promote axon regeneration, thereby minimizing the loss of vision or visual function associated with the ocular disorder.

Novel methods are provided for modulating CNS cell neogenesis in the CNS cells in vitro or in vivo, involving the use of agents that decrease the activity of the melanocortin 4 receptor (MC4R). When the methods of the invention are applied to a subject such as a human, it may be used for reducing a symptom of a CNS disorder.

A method of cosmetically treating a superficial area of mammalian skin by irradiating the skin with a source of divergent electromagnetic radiation of between 900 nm to 1500 nm, and use of electromagnetic radiation of specified wavelengths. The cosmetic treatment includes reducing or alleviating or removing or diminishing wrinkles or fine lines, rejuvenating skin, retarding or reversing visible signs of aging, improving skin elasticity, tone, texture and appearance and beautifying facial, breast, arm, buttock, thigh, stomach or neck skin.

Dehydrated, edible, high-protein food products formed of cultured muscle cells that are combined (e.g., mixed) with a hydrogel (e.g., a plant-derived polysaccharide) are described. These food products may be formed into a chip (e.g., snack chip), that has a protein content of greater than 50%. One or more flavorants may also be included.

The present disclosure provides an engineered collagen composition comprising collagen, wherein the collagen composition is compressed to form a gradient of at least one physical property. Methods of using and of manufacturing the engineered collagen compositions of the present disclosure are also provided.

The present invention relates to a composition and method for preventing and treating cancer and modulating cell proliferation using compositions extracted from pinoresinol-rich Olea europaea Caiazzana olives. The present invention provides contacting one or more cells with a pharmaceutical effective amount of a polyphenolic composition isolated from Olea europaea Caiazzana olives. The polyphenolic composition includes one or more polyphenolic compounds extracted from Olea europaea Caiazzana olives.

A method for evaluation of a compound comprising the steps of introducing an RSK1 gene into a cell to prepare a cell capable of expressing RSK1, contacting a compound to be evaluated with the cell, and detecting the specific binding of the compound to RSK1; and a compound given by the method. The compound can be used as a potentiator of cisplatin. The method enables to find a gene which acts specifically on a cell of cancer induced by the abnormality in p53 or enhanced MAPK pathway and to evaluate a compound by using the gene.

Provided herein are methods and compositions for editing the genome of a cell. In some embodiments, a nucleotide sequence of at least 200 nucleotides in length is inserted into a target region in the genome of a cell.

The invention relates to human neutralizing anti-KIT antibodies and uses thereof. More particularly, the invention relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.

Disclosed are histone deacetylase (HDAC) inhibitors, or combinations comprising an HDAC inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of chronic lymphocytic leukemia in a subject in need thereof. Also provided herein are methods for treating chronic lymphocytic leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor. Other related methods are disclosed.

The present disclosure shows, unexpectedly, that variations in cell culture performance in large-scale cell culture systems such as, for example, those used in commercial manufacturing processes, in some instances, can be attributed to often subtle variations among shear-protectant additives used during cell culture. Assessing the quality of shear-protective additives using such large-scale systems, however, is inaccurate, time-consuming and costly. To solve the problem identified, the present disclosure provides methods and compositions for evaluating the suitability of shear-protectant additives without resorting to large scale cell growth and/or protein production tests.

The invention discloses a method for regulating osmotic pressure stress of Pseudomonas glabrata, belonging to the field of bioengineering. The invention regulates the osmotic stress resistance of Pseudomonas glabrata by overexpressing or deleting the coding gene CgRDS2 of the native transcription factor. The results showed that the biomass, cell viability and membrane integrity of Pseudomonas glabrata decreased by 23%, 46% and 47.6%, respectively, under osmotic stress compared with wild-type strain after the deletion of CgRDS2 gene. After overexpression of CgRDS2 gene, the biomass increased by10%, cell viability increased by 39% and cell membrane integrity increased by 12.1% under 1.5 M NaCl stress.

Compositions for improved gene editing and methods of use thereof are disclosed. In a preferred method, gene editing involves use of a cell-penetrating anti-DNA antibody, such as 3E10, as a potentiating agent to enhance gene editing by nucleases and triplex forming oligonucleotides. Genomic modification occurs at a higher frequency when cells are contacted with the potentiating agent and nuclease or triplex forming oligonucleotide, as compared to the absence of the potentiating agent. The methods are suitable for both ex vivo and in vivo approaches to gene editing and are useful for treating a subject with a genetic disease or disorder. Nanoparticle compositions for intracellular delivery of the gene editing compositions are provided and are particularly advantageous for use with in vivo applications.

The invention relates to a preparation method and an application of zwitterionic polymer-curcumin self-assembly nano-particles for inhibiting beta-amyloid protein aggregation. According to the method,polyphenol micro-molecule curcumin with the function of inhibiting A beta aggregation is started, esterification reaction is performed according to strong hydrophobicity characteristics of curcumin and lively-OH at two ends of the curcumin, and zwitterionic polymer-polymethylacrylic acid carboxyl betaine with strong hydrophilicity is modified on the curcumin to obtain an amphipathic substance Curcumin-pCBMA. As Cur@pCB has a strong hydrophobicity portion and a strong hydrophilicity portion, the Cur@pCB can be automatically assembled in a water environment system to form a nano-scale micelle structure, the self-assembly nano-structure can improve the characteristic of the curcumin insoluble in water, an A beta monomer combined with the curcumin is stabilized through the isolation action ofnano-micelle, so that the A beta monomer is difficultly aggregated, and inhibiting effects are improved. The self-assembly nano-particles are used as raw materials of medicines for treating related diseases caused by the beta-amyloid protein aggregation.